Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Methods to Develop an in silico Clinical Trial, Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate

  • Gutiérrez-Casares, José Ramón
  • Quintero, Javier
  • Jorba, Guillem|||0000-0001-5209-5353
  • Junet, Valentin|||0000-0002-6138-0612
  • Martínez Perea, Vicente|||0000-0001-5193-715X
  • Pozo-Rubio, Tamara
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Mas, José Manuel
  • Montoto, Carmen
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with great molecular detail. Herein, we have applied a mechanistic head-to-head in silico clinical trial (ISCT) between two treatments for attention-deficit/hyperactivity disorder, to wit lisdexamfetamine (LDX) and methylphenidate (MPH). The ISCT was generated through three phases comprising (i) the molecular characterization of drugs and pathologies, (ii) the generation of adult and children virtual populations (vPOPs) totaling 2,600 individuals and the creation of physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models, and (iii) data analysis with artificial intelligence methods. The characteristics of our vPOPs were in close agreement with real reference populations extracted from clinical trials, as did our PBPK models with in vivo parameters. The mechanisms of action of LDX and MPH were obtained from QSP models combining PBPK modeling of dosing schemes and systems biology-based modeling technology, i.e., therapeutic performance mapping system. The step-by-step process described here to undertake a head-to-head ISCT would allow obtaining mechanistic conclusions that could be extrapolated or used for predictions to a certain extent at the clinical level. Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

  • Coto-Segura, P|||0000-0002-6455-4825
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Martorell, Antonio|||0000-0003-1378-1590
  • Moreno-Ramírez, David|||0000-0002-1301-7974
  • Jorba, Guillem|||0000-0001-5209-5353
  • Junet, Valentin|||0000-0002-6138-0612
  • Guerri, Filippo
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Cara, Carlos
  • Suárez-Magdalena, Olaya
  • Abraham, Sonya
  • Mas, José Manuel
Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based on patient profiles. We built a quantitative systems pharmacology (QSP) model of a clinical trial-like vPop with moderate-to-severe psoriasis treated with two dosing schemes of CZP (200 mg and 400 mg, both every two weeks for 16 weeks, starting with a loading dose of CZP 400 mg at weeks 0, 2, and 4). We applied different modelling approaches: (i) an algorithm to generate vPop according to reference population values and comorbidity frequencies in real-world populations; (ii) physiologically based pharmacokinetic (PBPK) models of CZP dosing schemes in each virtual patient; and (iii) systems biology-based models of the mechanism of action (MoA) of the drug. The combination of our different modelling approaches yielded a vPop distribution and a PBPK model that aligned with existing literature. Our systems biology and QSP models reproduced known biological and clinical activity, presenting outcomes correlating with clinical efficacy measures. We identified distinct clusters of virtual patients based on their psoriasis-related protein predicted activity when treated with CZP, which could help unravel differences in drug efficacy in diverse subpopulations. Moreover, our models revealed clusters of MoA solutions irrespective of the dosing regimen employed. Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba Argemí, Guillem
  • Aguirre Plans, Joaquim, 1993-
  • Junet, Valentin
  • Segú-Vergés, Cristina
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/., Public funders provided support for authors salaries: JAP, NFF and BO received support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; “Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. GJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158. Funding for publication is from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

  • Artigas, Laura
  • Coma Camprodón, Mireia
  • Matos Filipe, Pedro
  • Aguirre Plans, Joaquim, 1993-
  • Farrés, Judith
  • Valls, Raquel
  • Fernández Fuentes, Narcís
  • Haba-Rodríguez, Juan de la
  • Olvera, Alex
  • Barbera, Jose
  • Morales-Barrera, Rafael
  • Oliva Miguel, Baldomero
  • Mas, José Manuel
From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications., LA, MC, PMF, JF, RV and JMM have commercial affiliation to Anaxomics Biotech SL. The funders provided support in the form of salaries for authors JAP, NFF and PMF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. JAP, NFF and BO acknowledge support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370].PMF has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Methods to develop an in silico clinical trial: computational head-to-head comparison of lisdexamfetamine and methylphenidate

  • Gutiérrez-Casares, José Ramón
  • Quintero, Javier
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Martínez, Vicente
  • Pozo-Rubio, Tamara
  • Oliva Miguel, Baldomero
  • Daura, Xavier
  • Mas, José Manuel
  • Montoto, Carmen
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with great molecular detail. Herein, we have applied a mechanistic head-to-head in silico clinical trial (ISCT) between two treatments for attention-deficit/hyperactivity disorder, to wit lisdexamfetamine (LDX) and methylphenidate (MPH). The ISCT was generated through three phases comprising (i) the molecular characterization of drugs and pathologies, (ii) the generation of adult and children virtual populations (vPOPs) totaling 2,600 individuals and the creation of physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models, and (iii) data analysis with artificial intelligence methods. The characteristics of our vPOPs were in close agreement with real reference populations extracted from clinical trials, as did our PBPK models with in vivo parameters. The mechanisms of action of LDX and MPH were obtained from QSP models combining PBPK modeling of dosing schemes and systems biology-based modeling technology, i.e., therapeutic performance mapping system. The step-by-step process described here to undertake a head-to-head ISCT would allow obtaining mechanistic conclusions that could be extrapolated or used for predictions to a certain extent at the clinical level. Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine., This study was funded by Takeda. Public funders provided support for some of the authors' salaries: GJ has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765158.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

  • Carcereny, Enric
  • Fernández Nistal, Alonso
  • López, Araceli
  • Montoto, Carmen
  • Naves, Andrea
  • Segú-Vergés, Cristina
  • Coma Camprodón, Mireia
  • Jorba Argemí, Guillem
  • Oliva Miguel, Baldomero
  • Mas, José Manuel
Around 3-7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyrosine kinase inhibitors (TKIs), such as crizotinib, ceritinib, alectinib, brigatinib and lorlatinb present good performance treating ALK+ NSCLC, although all patients invariably develop resistance due to ALK secondary mutations or bypass mechanisms. In the present study, we compare the potential differences between brigatinib and alectinib's mechanisms of action as first-line treatment for ALK+ NSCLC in a systems biology-based in silico setting. Therapeutic performance mapping system (TPMS) technology was used to characterize the mechanisms of action of brigatinib and alectinib and the impact of potential resistances and drug interferences with concomitant treatments. The analyses indicate that brigatinib and alectinib affect cell growth, apoptosis and immune evasion through ALK inhibition. However, brigatinib seems to achieve a more diverse downstream effect due to a broader cancer-related kinase target spectrum. Brigatinib also shows a robust effect over invasiveness and central nervous system metastasis-related mechanisms, whereas alectinib seems to have a greater impact on the immune evasion mechanism. Based on this in silico head to head study, we conclude that brigatinib shows a predicted efficacy similar to alectinib and could be a good candidate in a first-line setting against ALK+ NSCLC. Future investigation involving clinical studies will be needed to confirm these findings. These in silico systems biology-based models could be applied for exploring other unanswered questions.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

  • Coto-Segura, Pablo
  • Segú-Vergés, Cristina
  • Martorell, Antonio
  • Moreno-Ramírez, David
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Guerri, Filippo
  • Daura, Xavier
  • Oliva Miguel, Baldomero
  • Cara, Carlos
  • Suárez-Magdalena, Olaya
  • Abraham, Sonya
  • Mas, José Manuel
Background: Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based on patient profiles. Methods: We built a quantitative systems pharmacology (QSP) model of a clinical trial-like vPop with moderate-to-severe psoriasis treated with two dosing schemes of CZP (200 mg and 400 mg, both every two weeks for 16 weeks, starting with a loading dose of CZP 400 mg at weeks 0, 2, and 4). We applied different modelling approaches: (i) an algorithm to generate vPop according to reference population values and comorbidity frequencies in real-world populations; (ii) physiologically based pharmacokinetic (PBPK) models of CZP dosing schemes in each virtual patient; and (iii) systems biology-based models of the mechanism of action (MoA) of the drug. Results: The combination of our different modelling approaches yielded a vPop distribution and a PBPK model that aligned with existing literature. Our systems biology and QSP models reproduced known biological and clinical activity, presenting outcomes correlating with clinical efficacy measures. We identified distinct clusters of virtual patients based on their psoriasis-related protein predicted activity when treated with CZP, which could help unravel differences in drug efficacy in diverse subpopulations. Moreover, our models revealed clusters of MoA solutions irrespective of the dosing regimen employed. Conclusion: Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses., The study was funded by UCB Pharma and Anaxomics Biotech. Copy-editing was funded by UCB Pharma. Article processing fees were provided by UCB Pharma. Public funders provided support for some of the authors’ salaries: VJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158 (COSMIC; www.cosmic-h2020.eu); GJ has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912; FG has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 813545. The funder UCB Biopharma was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

The mito-QC Reporter for Quantitative Mitophagy Assessment in Primary Retinal Ganglion Cells and Experimental Glaucoma Models

  • Rosignol, Ines
  • Villarejo-Zori, Beatriz
  • Teresak, Petra
  • Sierra-Filardi, Elena
  • Pereiro Díez, Xandra
  • Rodríguez Muela, Natalia
  • Vecino Cordero, Elena
  • Vieira, Helena L. A.
  • Bell, Katharina
  • Boya, Patricia
Mitochondrial damage plays a prominent role in glaucoma. The only way cells can degrade whole mitochondria is via autophagy, in a process called mitophagy. Thus, studying mitophagy in the context of glaucoma is essential to understand the disease. Up to date limited tools are available for analyzing mitophagy in vivo. We have taken advantage of the mito-QC reporter, a recently generated mouse model that allows an accurate mitophagy assessment to fill this gap. We used primary RGCs and retinal explants derived from mito-QC mice to quantify mitophagy activation in vitro and ex vivo. We also analyzed mitophagy in retinal ganglion cells (RGCs), in vivo, using different mitophagy inducers, as well as after optic nerve crush (ONC) in mice, a commonly used surgical procedure to model glaucoma. Using mito-QC reporter we quantified mitophagy induced by several known inducers in primary RGCs in vitro, ex vivo and in vivo. We also found that RGCs were rescued from some glaucoma relevant stress factors by incubation with the iron chelator deferiprone (DFP). Thus, the mito-QC reporter-based model is a valuable tool for accurately analyzing mitophagy in the context of glaucoma., This research was funded by Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) PGC2018-098557-B-I00 and European Union’s Horizon 2020 research and innovation programme under grant agreement No 765912. BVZ is a recipient of PhD contract from the Fundación Tatiana Pérez de Guzmán el Bueno (Spain), PT from H2020-MSCA-ITN-2017, NRM a Juan de la Cierva Grant from Ministerio Ciencia e Innovación (Spain) and KB from DFG (Deutsche Forschungsgemeinschaft, Germany, 6619/1-1).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autophagy in stem cells: repair, remodelling and metabolic reprogramming

  • Boya, Patricia
  • Codogno, Patrice
  • Rodríguez-Muela, N.
14 p.-6 fig., Autophagy is a catabolic pathway by which cellular components are delivered to the lysosome for degradation and recycling. Autophagy serves as a crucial intracellular quality control and repair mechanism but is also involved in cell remodelling during development and cell differentiation. In addition, mitophagy, the process by which damaged mitochondria undergo autophagy, has emerged as key regulator of cell metabolism. In recent years, a number of studies have revealed roles for autophagy and mitophagy in the regulation of stem cells, which represent the origin for all tissues during embryonic and postnatal development, and contribute to tissue homeostasis and repair throughout adult life. Here, we review these studies, focussing on the latest evidence that supports the quality control, remodelling and metabolic functions of autophagy during the activation, self-renewal and differentiation of embryonic, adult and cancer stem cells., P.B. is supported by Spain's Ministerio de Economía y Competitividad [BFU2015-65623 (FEDER funding) and BFU2015-71869-REDT], European Cooperation in Science and Technology (COST) Action Transautophagy (CA15138) and the European Union Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) under grant agreement 765912. N.R.-M. is supported by a grant from the Muscular Dystrophy Association (MDA376743) and a Juan de la Cierva Incorporación fellowship from Spain's Ministerio de Economía y Competitividad. P.C. is supported by funding from the Institut National de la Santé et de la Recherche Médicale (INSERM), the Centre National de la Recherche Scientifique (CNRS), and Université Paris Descartes-Sorbonne Paris Cité and grants from the Institut National Du Cancer (INCa) and the Agence Nationale de la Recherche (ANR)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy

  • Kraft, Claudine
  • Boya, Patricia
  • Codogno, Patrice
  • Elazar, Zvulun
  • Eskelinen, Eeva-Liisa
  • Farrés, Judith
  • Kirkin, Vladimir
  • Jungbluth, Heinz
  • Martínez Gil, Ana
  • Pless, Ole
  • Primard, Charlotte
  • Proikas-Cezanne, Tassula
  • Simonsen, Anne
  • Reggiori, Fulvio
.DRIVE is supported by a MarieSkłodowska-Curie ETN grant under theEuropean Union’s Horizon 2020 Research and Innovation Programme(Grant Agreement No 765912). P.B. is also supported by the Ministerio de Ciencia, Innovación y Universidades (BFU2015-65623) and by Redes de laComunidad de Madrid 2017/BMD-3813. Work in P.C. laboratory is sup-ported by institutional fundings from INSERM, CNRS and University ParisDescartes and by grants from Agence Nationale pour la Recherche (ANR) andFondation pour la Recherche Médicale(FRM). Z.E. research is supported bythe Israel Science Foundation ISF, the Legacy Heritage Fund and theWeizmann Institute Minerva center. E.-L.E. is also supported by TheAcademy of Finland project grant (286787), by Magnus EhrnroothFoundation, and by COST Action 15138 Transautophagy. V.K. is also sup-ported by the CRUK programme grant C2739/A22897. C.K. is also supportedby funding from the Vienna Science and Technology Fund (WWTF, VRG10-001) from the FWF Austrian Science Fund (P28113-B28), from the EuropeanResearch Council (ERC) under the European Union’s Horizon 2020 Researchand Innovation Programme (grant agreement No 769065), and from theEMBO Young Investigator Program. H.J. is supported by a grant fromAction Medical Research (Grant reference GN 2446), United Kingdom. O.P.is also supported by the German Federal Ministry of Education and Research(BMBF) (01EK1608B and 13GW0128B). T.P.-C. is also supported by theGerman Research Foundation (Deutsche Forschungsgemeinschaft, DFG);SFB/TRR 209 (project B02); FOR 2625 (project 1). A.S. is also supported bythe Research Council of Norway (project # 221831 and through its Centres ofExcellence funding scheme project # 262652) and the Norwegian CancerSociety (project #190251). F.R. is also supported by ZonMW VICI(016.130.606), ZonMW TOP (91217002), ALW Open Programme(ALWOP.310) and Marie Skłodowska-Curie Cofund (713660) grant, DRIVEis supported by a MarieSkłodowska-Curie ETN grant under the European Union’s Horizon 2020 Research and Innovation Programme(Grant Agreement No 765912). P.B. is also supported by the Ministerio deCiencia, Innovación y Universidades (BFU2015-65623) and by Redes de la Comunidad de Madrid 2017/BMD-3813. Work in P.C. laboratory is sup-ported by institutional fundings from INSERM, CNRS and University ParisDescartes and by grants from Agence Nationale pour la Recherche (ANR) andFondation pour la Recherche Médicale(FRM). Z.E. research is supported bythe Israel Science Foundation ISF, the Legacy Heritage Fund and theWeizmann Institute Minerva center. E.-L.E. is also supported by The Academy of Finland project grant (286787), by Magnus EhrnroothFoundation, and by COST Action 15138 Transautophagy. V.K. is also sup-ported by the CRUK programme grant C2739/A22897. C.K. is also supportedby funding from the Vienna Science and Technology Fund (WWTF, VRG10-001) from the FWF Austrian Science Fund (P28113-B28), from the EuropeanResearch Council (ERC) under the European Union’s Horizon 2020 Researchand Innovation Programme (grant agreement No 769065), and from the EMBO Young Investigator Program. H.J. is supported by a grant fromAction Medical Research (Grant reference GN 2446), United Kingdom. O.P.is also supported by the German Federal Ministry of Education and Research(BMBF) (01EK1608B and 13GW0128B). T.P.-C. is also supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG);SFB/TRR 209 (project B02); FOR 2625 (project 1). A.S. is also supported by the Research Council of Norway (project # 221831 and through its Centres ofExcellence funding scheme project # 262652) and the Norwegian CancerSociety (project #190251). F.R. is also supported by ZonMW VICI(016.130.606), ZonMW TOP (91217002), ALW Open Programme(ALWOP.310) and Marie Skłodowska-Curie Cofund (713660) grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases

  • Maestro, Inés
  • Boya, Patricia
  • Martínez Gil, Ana
13 p.-5 fig.-1 tab., Introduction: Autophagy, a basic cellular degradation pathway essential for survival, is altered both in aging and in many chronic human diseases, including infections, cancer, heart disease, and neurodegeneration. Identifying new therapeutic targets for the control and modulation of autophagy events is therefore of utmost importance in drug discovery. Serum and glucocorticoid activated kinase 1 (SGK1), known for decades for its role in ion channel modulation, is now known to act as a switch for autophagy homeostasis, and has emerged as a novel and important therapeutic target likely to attract considerable research attention in the coming years., Areas covered: In this general review of SGK1 we describe the kinase’s structure and its roles in physiological and pathological contexts. We also discuss small-molecule modulators of SGK1 activity. These modulators are of particular interest to medicinal chemists and pharmacists seeking to develop more potent and selective drug candidates for SGK1, which, despite its key role in autophagy, remains relatively understudied., Expert opinion: The main future challenges in this area are (i) deciphering the role of SGK1 in selective autophagy processes (e.g. mitophagy, lipophagy, and aggrephagy); (ii) identifying selective allosteric modulators of SGK1 with specific biological functions; and (iii) conducting first-in-man clinical studies., Funding support was provided by European Union (EU) (H2020-MSCA-ITN-2017 (grant no. 765912, DRIVE Driving next generation autophagy researchers towards translation); the Autonomous Community of Madrid (CM) (grant no. BMD-3813 ELA_Madrid); and Spanish Ministry of Research and Science (MCIU) and State Research Agency (AEI) (grant numbers PGC2018-098557-B-I00 to P.B. and SAF2016-76693-R to A.M))., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The mito-QC Reporter for Quantitative Mitophagy Assessment in Primary Retinal Ganglion Cells and Experimental Glaucoma Models

  • Rosignol, Ines
  • Villarejo-Zori, Beatriz
  • Teresak, Petra
  • Sierra-Filardi, Elena
  • Pereiro, Xandra
  • Rodríguez-Muela, N.
  • Vecino, Elena
  • Vieira, Helena L. A.
  • Bell, Katharina
  • Boya, Patricia
© 2020 by the authors., Mitochondrial damage plays a prominent role in glaucoma. The only way cells can degrade whole mitochondria is via autophagy, in a process called mitophagy. Thus, studying mitophagy in the context of glaucoma is essential to understand the disease. Up to date limited tools are available for analyzing mitophagy in vivo. We have taken advantage of the mito-QC reporter, a recently generated mouse model that allows an accurate mitophagy assessment to fill this gap. We used primary RGCs and retinal explants derived from mito-QC mice to quantify mitophagy activation in vitro and ex vivo. We also analyzed mitophagy in retinal ganglion cells (RGCs), in vivo, using different mitophagy inducers, as well as after optic nerve crush (ONC) in mice, a commonly used surgical procedure to model glaucoma. Using mito-QC reporter we quantified mitophagy induced by several known inducers in primary RGCs in vitro, ex vivo and in vivo. We also found that RGCs were rescued from some glaucoma relevant stress factors by incubation with the iron chelator deferiprone (DFP). Thus, the mito-QC reporter-based model is a valuable tool for accurately analyzing mitophagy in the context of glaucoma., This research was funded by Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) PGC2018-098557-B-I00 and European Union’s Horizon 2020 research and innovation programme under grant agreement No 765912. BVZ is a recipient of PhD contract from the Fundación Tatiana Pérez de Guzmán el Bueno (Spain), PT from H2020-MSCA-ITN-2017, NRM a Juan de la Cierva Grant from Ministerio Ciencia e Innovación (Spain) and KB from DFG (Deutsche Forschungsgemeinschaft, Germany, 6619/1-1)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

COVID-19: Drug targets and potential treatments

  • Gil, Carmen
  • Ginex, Tiziana
  • Maestro, Inés
  • Nozal, Vanesa
  • Barrado-Gil, Lucía
  • Cuesta-Geijo, Miguel Ángel
  • Urquiza, Jesús
  • Ramírez, David
  • Alonso Martí, Covadonga
  • Campillo, Nuria E.
  • Martínez Gil, Ana
92 p.-22 fig.-1 tab.-1 graph. abst., Currently, we are immersed in a pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which severely threatens public health worldwide. Until now, no drug or vaccine has been approved to treat the severe disease caused by this coronavirus, COVID-19. We will focus on the main virus-based and host-based targets that can guide medicinal chemistry efforts to discover new drugs for this devastating disease. In principle, all CoVs enzymes and proteins involved in viral replication and the control of host cellular machineries are potentially druggable targets in the search for therapeutic options for SARS-CoV-2. This perspective provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of innate immune response to coronavirus infection and the related therapeutic options will be presented., Funding from CSIC (201980E024 and 202020E103) is acknowledged. This research was partially supported through "la Caixa" Banking Foundation (HR18-00469), Instituto de Salud Carlos III (ISCIII-COV20/01007), Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00), CONICYT-PCI (REDES190074 to D. R. and A. M.) and FONDECYT (11180604 to D.R.). I. M. was funded by H2020-MSCA-ITN-2017 (grant no. 765912), V. N. holds a pre-doctoral FPU grant (FPU16/04466) and J. U. was financed by FPI-SGIT2018-04., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HIF1α or mitophagy: which drives cardiomyocyte differentiation?

  • Villarejo-Zori, Beatriz
  • Jiménez-Loygorri, Juan Ignacio
  • Boya, Patricia
4 p.-1 fig., Research in the P.B. lab is supported by grants PGC2018-098557-B-I00 from Spain’s Ministerio Ciencia e Innovación, and funding from the European Union’s Horizon 2020 re-search and innovation programme under grant agreement No. 765912., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitophagy Modulation, a New Player in the Race against ALS

  • Madruga, Enrique
  • Maestro, Inés
  • Martínez Gil, Ana
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease that usually results in respiratory paralysis in an interval of 2 to 4 years. ALS shows a multifactorial pathogenesis with an unknown etiology, and currently lacks an effective treatment. The vast majority of patients exhibit protein aggregation and a dysfunctional mitochondrial accumulation in their motoneurons. As a result, autophagy and mitophagy modulators may be interesting drug candidates that mitigate key pathological hallmarks of the disease. This work reviews the most relevant evidence that correlate mitophagy defects and ALS, and discusses the possibility of considering mitophagy as an interesting target in the search for an effective treatment for ALS., This work is supported by H2020-MSCA-ITN-2017 (grant no. 765912, DRIVE Driving next generation autophagy researchers towards translation, 01 November 2017), the Autonomous Community of Madrid (grant no. BMD-3813 ELA_Madrid, 01 January 2018), MCIU (grant PID2019-105600RB-I00, 01/06/2020) and ISCiii CIBERNED (CB18/05/00040, 01 January 2019)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulation of PRKN-independent mitophagy

  • Teresak, Petra
  • Lapao, Ana
  • Subic, Nemanja
  • Boya, Patricia
  • Elazar, Zvulun
  • Simonsen, Anne
37 p.-3 fig.-1 tab., Mitochondria are dynamic, multifunctional cellular organelles that play a fundamental role in maintaining cellular homeostasis. Keeping the quality of mitochondria in check is of essential importance for functioning and survival of the cells. Selective autophagic clearance of flawed mitochondria, a process termed mitophagy, is one of the most prominent mechanisms through which cells maintain a healthy mitochondrial pool. The best-studied pathway through which mitophagy is exerted is the PINK1-PRKN pathway. However, an increasing number of studies have shown an existence of alternative pathways, where different proteins and lipids are able to recruit autophagic machinery independently of PINK1 and PRKN. The significance of PRKN-independent mitophagy pathways is reflected in various physiological and pathophysiological processes, but many questions regarding the regulation and the interplay between these pathways remain open. Here we review the current knowledge and recent progress made in the field of PRKN-independent mitophagy. Particularly we focus on the regulation of various receptors that participate in targeting impaired mitochondria to autophagosomes independently of PRKN., We are grateful for funding from the Israel Science Foundation (Grant #215/19), the Sagol Longevity Foundation, Joint NRF - ISF Research Fund (Grant #3221/19), and the Yeda-Sela Center for Basic Research, as well as the Research Council of Norway through its Centres of Excellence funding scheme (project number 262652 to AS) and FRIPRO (project number 221831 to AS) and the Norwegian Cancer Society (project number 171318 to AS). Research in PB lab is supported by (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) PGC2018-098557-B-I00 Neuroscience Projects from Fundación Tatiana Pérez de Guzmán el Bueno and 2017/BMD-3813 from Comunidad de Madrid. The first authors are supported by a Marie Skłodowska-Curie ETN grant under the European Union’s Horizon 2020 Research and Innovation Programme (Grant Agreement No 765912 DRIVE), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

  • Ginex, Tiziana
  • Garaigorta, Urtzi
  • Ramírez, David
  • Castro, Victoria
  • Nozal, Vanesa
  • Maestro, Inés
  • Garcia-Carceles, Javier
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Gastaminza, Pablo
  • Gil, Carmen
The unprecedent situation generated by the COVID-19 global emergency has prompted us to actively work to fight against this pandemic by searching for repurposable agents among FDA approved drugs to shed light into immediate opportunities for the treatment of COVID-19 patients. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. To this end a multi-target virtual screening approach focused on host-based targets related to viral entry, followed by the experimental evaluation of the antiviral activity of selected compounds, has been carried out. As a result, five different potentially repurposable drugs interfering with viral entry—cepharantine, clofazimine, metergoline, imatinib and efloxate—have been identified, This research was funded by CSIC (201980E024, 202020E103 and PIE-RD-COVID-19 ref. E202020E079), EVA (European Virus Archive; grant agreement No 871029), ANID (Agencia Nacional de Investigación y Desarrollo de Chile, grant No COVID0199), and CONICYT-PCI (Comisión Nacional de Investigación Científica y Tecnológica de Chile—Programa de Cooperación Internacional, grant No REDES190074). I.M. was funded by H2020-MSCA-ITN-2017 (grant no. 765912) and V.N. holds a pre-doctoral FPU grant (FPU16/04466), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting autophagy in disease: established and new strategies

  • Kocak, Muhammed
  • Ezazi Erdib, Saba
  • Jorba, Guillem
  • Maestro, Inés
  • Farrés, Judith
  • Kirkin, Vladimir
  • Martínez Gil, Ana
  • Pless, Ole
Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible., This research was funded by H2020 MarieSkłodowska-Curie Actions (765912 - DRIVE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

New insights into the role of autophagy in retinal and eye diseases

  • Villarejo-Zori, Beatriz
  • Jiménez-Loygorri, Juan Ignacio
  • Zapata-Muñoz, Juan
  • Bell, Katharina
  • Boya, Patricia
18 p.-4 fig., Autophagy is a fundamental homeostatic pathway that mediates the degradation and recycling of intracellular components. It serves as a key quality control mechanism, especially in non-dividing cells such as neurons. Proteins, lipids, and even whole organelles are engulfed in autophagosomes and delivered to the lysosome for elimination. The retina is a light-sensitive tissue located in the back of the eye that detects and processes visual images. Vision is a highly demanding process, making the eye one of the most metabolically active tissues in the body and photoreceptors display glycolytic metabolism, even in the presence of oxygen. The retina and eye are also exposed to other stressors that can impair their function, including genetic mutations and age-associated changes. Autophagy, among other pathways, is therefore a key process for the preservation of retinal homeostasis. Here, we review the roles of both canonical and non-canonical autophagy in normal retinal function. We discuss the most recent studies investigating the participation of autophagy in eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy and its role protecting photoreceptors in several forms of retinal degeneration. Finally, we consider the therapeutic potential of strategies that target autophagy pathways to treat prevalent retinal and eye diseases., Research in the P.B. lab is supported by funding (PGC2018-098557-B-I00) from Spain's Ministerio Ciencia e Innovación, Agencia Estatal de Investigación (AEI), the Fondo Europeo de Desarrollo Regional (FEDER), the European Union's Horizon 2020 research and innovation program (grant agreement No 765912), the Fundación Tatiana Pérez de Guzmán el Bueno Proyectos en Neurociencia 2018, and Redes de BioMedicina de la Comunidad de Madrid (BMD-3813)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Towards a better understanding of the neuro-developmental role of autophagy in sickness and in health

  • Zapata-Muñoz, Juan
  • Villarejo-Zori, Beatriz
  • Largo-Barrientos, Pablo
  • Boya, Patricia
Autophagy is a critical cellular process by which biomolecules and cellular organelles are degraded in an orderly manner inside lysosomes. This process is particularly important in neurons: these post-mitotic cells cannot divide or be easily replaced and are therefore especially sensitive to the accumulation of toxic proteins and damaged organelles. Dysregulation of neuronal autophagy is well documented in a range of neurodegenerative diseases. However, growing evidence indicates that autophagy also critically contributes to neurodevelopmental cellular processes, including neurogenesis, maintenance of neural stem cell homeostasis, differentiation, metabolic reprogramming, and synaptic remodelling. These findings implicate autophagy in neurodevelopmental disorders. In this review we discuss the current understanding of the role of autophagy in neurodevelopment and neurodevelopmental disorders, as well as currently available tools and techniques that can be used to further investigate this association., Research in the P.B. lab is supported by grant (PGC2018-098557-B-I00) from Spain’s Ministerio Ciencia e Innovación, the Agencia Estatal de Investigación (AEI), the Fondo Europeo de Desarrollo Regional (FEDER), and funding from the European Union’s Horizon 2020 Research and Innova-tion Programme under grant agreement No. 765912, Fundación Tatiana Pérez de Guzmán el Bueno Proyectos en Neurociencia 2018, and Redes de BioMedicina de la Co-munidad de Madrid, BMD-3813. JZM is a recipient of a FPU fellowship (Ministerio de Universidades)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phenotypic assay leads to discovery of mitophagy inducers with therapeutic potential for Parkinson’s disease

  • Maestro, Inés
  • De la Ballina, Laura R.
  • Simonsen, Anne
  • Boya, Patricia
  • Martínez Gil, Ana
12 p.-9 fig.-2 tab.-1 graph. abst., Mitophagy, the selective degradation of mitochondria by autophagy, involved in important physiological processes and defects in pathways has been reported in pathological conditions, such as neurodegeneration. Thus, mitophagy is an interesting target for drug discovery programs. In this investigation, we used robust phenotypic assay to screen a set of 50 small heterocyclic compounds to identify inducers of mitophagy. We identified two compounds, VP07 and JAR1.39, that induce Parkin-dependent mitophagy. Based on structure–activity relationship studies, we proposed the ability of the compounds to act as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin. Finally, we show promising therapeutic applicability in a cellular model of Parkinson’s disease., This research was supported by the H2020-MSCA-ITN-2017(grant no. 765912) DRIVE project, Spain’s Ministerio de Ciencia e Innovación (grant nos. PGC2018-098557-B-I00 to P.B. and PID2019-105600RB-I00 to A.M.), FRIPRO (project no. 221831 to A.S.), and the Research Council of Norway through its Centres of Excellence funding scheme (project no.262652)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular alterations in sporadic and SOD1-ALS immortalized lymphocytes: towards a personalized therapy

  • Lastres-Becker, Isabel
  • Porras, Gracia
  • Arribas-Blázquez, Marina
  • Maestro, Inés
  • Borrego-Hernández, Daniel
  • Boya, Patricia
  • Cerdán, Sebastián
  • García-Redondo, Alberto
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
17 p.-6 fig.-1 tab., Amyotrophic lateral sclerosis (ALS) is a fatal neurological condition where motor neurons (MNs) degenerate. Most of the ALS cases are sporadic (sALS), whereas 10% are hereditarily transmitted (fALS), among which mutations are found in the gene that codes for the enzyme superoxide dismutase 1 (SOD1). A central question in ALS field is whether causative mutations display selective alterations not found in sALS patients, or they converge on shared molecular pathways. To identify specific and common mechanisms for designing appropriate therapeutic interventions, we focused on the SOD1-mutated (SOD1-ALS) versus sALS patients. Since ALS pathology involves different cell types other than MNs, we generated lymphoblastoid cell lines (LCLs) from sALS and SOD1-ALS patients and healthy donors and investigated whether they show changes in oxidative stress, mitochondrial dysfunction, metabolic disturbances, the antioxidant NRF2 pathway, inflammatory profile, and autophagic flux. Both oxidative phosphorylation and glycolysis appear to be upregulated in lymphoblasts from sALS and SOD1-ALS. Our results indicate significant differences in NRF2/ARE pathway between sALS and SOD1-ALS lymphoblasts. Furthermore, levels of inflammatory cytokines and autophagic flux discriminate between sALS and SOD1-ALS lymphoblasts. Overall, different molecular mechanisms are involved in sALS and SOD1-ALS patients and thus, personalized medicine should be developed for each case., This research was funded by Comunidad de Madrid (grant ELA_Madrid B2017/BMD-3813 and S2017/BMD-3688), European Commission MSCA-ITN-ETN (grant DRIVE GA: 765912), ISCiii (CIBERNED CB18/05/000 and CB06/05/0089), Fundela (2019/00325/001) for I.L.-B. and AEI (grant PID2019-105600RB-I00) for, A.M. and I.L.-B., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autophagy and disease: new insights and challenges ahead

  • Boya, Patricia
2 p., Research in my laboratory is supported by funding (PGC 2018-098557-B-I00) from Spain's Ministerio Ciencia e Innovación, Agencia Estatal de Investigación (AEI), the Fondo Europeo de Desarrollo Regional (FEDER), the European Union's Horizon 2020 Research and Innovation Program (grant agreement No. 765912), the Fundación Tatiana Pérez de Guzmán el Bueno Proyectos en Neurociencia 2018, and Redes de BioMedicina de la Comunidad de Madrid (BMD-3813)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles

  • Nozal, Vanesa
  • Rojas-Prats, Elisa
  • Maestro, Inés
  • Gil, Carmen
  • Pérez, Daniel I.
  • Martínez Gil, Ana
14 p.-8 fig.-4 tab., Phosphodiesterase 7 (PDE7) is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP), an important cellular messenger. PDE7’s role in neurotransmission, expression profile in the brain and the druggability of other phosphodiesterases have motivated the search for potent inhibitors to treat neurodegenerative and inflammatory diseases. Different heterocyclic compounds have been described over the years; among them, phenyl-2-thioxo-(1H)-quinazolin-4-one, called S14, has shown very promising results in different in vitro and in vivo studies. Recently, polymeric nanoparticles have been used as new formulations to target specific organs and produce controlled release of certain drugs. In this work, we describe poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles loaded with S14. Their preparation, optimization, characterization and in vivo drug release profile are here presented as an effort to improve pharmacokinetic properties of this interesting PDE7 inhibitor., This research was supported by MINECO (grant RTC-2015-3439-1 and PID2019-105600RB-I00), ISCiii CIBERNED (CB18/05/00040), MECD (FPU14-00204 to E.R.-P. and FPU16-04466 to V.N.) and H2020-MSCA-ITN-2017 (grant no. 765912 to I.M.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ambra1 haploinsufficiency in CD1 mice results in metabolic alterations and exacerbates age-associated retinal degeneration

  • Ramírez-Pardo, Ignacio
  • Villarejo-Zori, Beatriz
  • Jiménez-Loygorri, Juan Ignacio
  • Sierra-Filardi, Elena
  • Alonso-Gil, Sandra
  • Mariño, Guillermo
  • de la Villa, P.
  • Fitze, Patrick S.
  • Fuentes, José M.
  • García-Escudero, Ramón
  • Ferrington, Deborah A.
  • Gómez-Sintes, Raquel
  • Boya, Patricia
22 p.-9 fig., Macroautophagy/autophagy is a key process in the maintenance of cellular homeostasis. The age-dependent decline in retinal autophagy has been associated with photoreceptor degeneration. Retinal dysfunction can also result from damage to the retinal pigment epithelium (RPE), as the RPE-retina constitutes an important metabolic ecosystem that must be finely tuned to preserve visual function. While studies of mice lacking essential autophagy genes have revealed a predisposition to retinal degeneration, the consequences of a moderate reduction in autophagy, similar to that which occurs during physiological aging, remain unclear. Here, we described a retinal phenotype consistent with accelerated aging in mice carrying a haploinsufficiency for Ambra1, a pro-autophagic gene. These mice showed protein aggregation in the retina and RPE, metabolic underperformance, and premature vision loss. Moreover, Ambra1+/gt mice were more prone to retinal degeneration after RPE stress. These findings indicate that autophagy provides crucial support to RPE-retinal metabolism and protects the retina against stress and physiological aging., This work was supported by the H2020 Excellent Science [No. 765912]; Instituto de Salud Carlos III,CiberNed [CB06/05/0041]; Spanish Ministry of Science and Innovation [RTI2018-098990-J-I00]; Spanish Ministry of Science and Innovation [PGC2018-098557-B-I00]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of a new structural family of SGK1 inhibitors as potential neuroprotective agents

  • Maestro, Inés
  • Madruga, Enrique
  • Boya, Patricia
  • Martínez Gil, Ana
12 p.-11 fig.-3 tab., SGK1 is a serine/threonine kinase involved in several neurodegenerative-related pathways such as apoptosis, neuroinflammation, ionic channel regulation, and autophagy, among others. Despite its potential role as a pharmacological target against this kind of diseases, there are no reported inhibitors able to cross the BBB so far, being a field yet to be explored. In this context, a structure-based virtual screening against this kinase was performed, pointing out the deazapurine moiety as an interesting and easy-to-derivatize scaffold. Moreover, these inhibitors are able to i) exert neuroprotection in an in vitro model of AD and ii) block mitophagy in a PRKN-independent manner, reinforcing the hypothesis of SGK1 inhibitors as neuroprotective chemical tools., This research was supported by the European Comission H2020-MSCA-ITN-2017 program (grant no. 765912, DRIVE Project), Ministerio de Ciencia e Innovación (grant PID2019-105600RB-I00), ISCiii (grant CB18/05/00040, CIBERNED) and CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGINGl+ (PTI-NEURO-AGING+), Fondos recuperación PT + Neuroaging., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Discovery of mitophagy inhibitors with therapeutic potential in different familial amyotrophic lateral sclerosis mutations

  • Maestro, Inés
  • De la Ballina, Laura R.
  • Porras, Gracia
  • Corrochano, Silvia
  • Lago, Eva de
  • Simonsen, Anne
  • Boya, Patricia
  • Martínez Gil, Ana
19 p.-7 fig., Mitophagy is the selective degradation of mitochondria by autophagy. It promotes the turnover of mitochondria and prevents the accumulation of dysfunctional mitochondria, which can lead to cellular degeneration. Mitophagy is known to be altered in several pathological conditions, especially in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). We recently demonstrated an increase in autophagy flux in lymphoblasts from ALS patients bearing a mutation in SOD1. Thus, the identification of mitophagy inhibitors may be a therapeutic option to recover mitochondrial homeostasis. Here, using a phenotypic mitophagy assay, we identified a new mitophagy inhibitor, the small molecule named IGS2.7 from the MBC library. Interestingly, the treatment of different cellular and in vivo models of ALS with mutations on SOD1 and TARDBP with this inhibitor restores autophagy to control levels. These results point mitophagy inhibitors, especially IGS2.7, to a new therapeutic approach for familial ALS patients., This research was supported by the European Commission H2020-MSCA-ITN-2017 program (grant no. 765912, DRIVE project), Madrid Community Biomedicine program (grant B2017/BMD-3813), ISCiii (grant CB18/05/00040, CIBERNED) and CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ (PTI-NEURO-AGING+), Fondos recuperación PT + Neuroaging., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Moduladores de mitofagia como fármacos innovadores en enfermedades neurodegenerativas

  • Maestro, Inés
181 p.-62 fig.-12 tab.-anexos, [EN]Mitophagy is the selective degradation of mitochondria by autophagy. It consists in the recruitment of defective or non-needed mitochondria in a double-membrane structure, called autophagosome, which transports the mitochondria to the lysosome, where it will be degraded. It is an important process in the maintenance of the cellular homeostasis. The accumulation of defective mitochondria due to a block in mitophagy, or a lack of healthy mitochondria due to excessive mitophagy, can cause a detrimental effect on cellular homeostasis. In fact, it is known to be altered in several pathological conditions, such as in cancer, heart diseases and especially in neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, or Amyotrophic Lateral Sclerosis.Thus, mitophagy rises as an interesting therapeutic target in the field of medicinal chemistry and drug discovery. The main objective of this thesis was the discovery of new mitophagy modulators, their characterization, and their therapeutic applicability on models of neurodegeneration. Starting from two chemical libraries with more than 3700 compunds, several filters like computational tools and selection of compounds based on chemical diversity were applied to reduce the number of compounds to be evaluated. Finally, 90 compounds were studied in a phenotypic mitophagy assay. Two mitophagy inducers and one inhibitor were obtained.The inducers, named JAR1.39 and VP07, belong to a family of compounds designed to allosterically target GSK3. However, their ability to induce mitophagy was independent of their role against GSK3, being their structure the responsible of their activity on mitophagy. They were evaluated in Parkinson’s disease cellular models, and they rescued the defective mitophagy characteristic of the disease., The inhibitor, known as IGS2.7, targets the kinase CK1. Anyhow, mitophagy inhibition appeared to be CK1-independent, being ULK1, a kinase involved in autophagy initation, proposed as the key in its role in autophagy. The therapeutic applicability of the inhibitor was evaluated in amyotrophic lateral sclerosis cellular and animal models. SOD1- and TDP-43-lymhoblasts of patients showed higher autophagy flux compared to control. Mice carrying a mutation in the same genes showed lower protein level of p62, an autophagy surrogate and TOMM20, a mitochondrial mass protein, thus suggesting higher mitophagy activity. The treatment of both cellular models and TDP-43 animal model with the inhibitor IGS2.7, restored autophagy flux and protein levels to control. In addition, the kinase SGK1 was found to be implicated in autophagy regulation. Thus, using a different approach, a virtual screening was done against the kinase. Then, we evaluated the inhibitory ability of the compounds against SGK1. The more potent compounds were studied in a mitophagy assay, and a decrease in mitophagy was obtained when SGK1 was inhibited. Interestingly, this mitophagy decrease came along with an increase in mitochondrial biogenesis. The therapeutic applicability of SGK1 inhibition was studied in an Alzheimer’s disease cellular model. The inhibition of the kinase restored cell death. Thus, we conclude that mitophagy and mitochondrial homeostasis are defective processes in several pathological conditions and their modulation is interesting to recover good levels of healthy mitochondria. Thus, these two therapeutic strategies can be used in the treatment of neurodegenerative diseases, where the processes are altered., [ES]La mitofagia es la degradación selectiva de la mitocondria mediante autofagia. A través de una estructura de doble membrana, conocida como autofagosoma, las mitocondrias defectuosas o que no hacen falta son llevadas al lisosoma, donde son degradadas. Se trata de un proceso clave en el mantenimiento de la homeostasis celular. Una acumulación de mitocondrias defectuosas o la falta de mitocondrias sanas causadas por un exceso o un defecto de mitofagia, afectan a la homeostasis celular. De hecho, es un proceso alterado en diferentes enfermedades, como en cáncer, enfermedades cardíacas y especialmente en enfermedades neurodegenerativas, como en la enfermedad de Parkinson, la enfermedad de Alzheimer, o en la esclerosis lateral amiotrófica. Así, la mitofagia aparece como una diana terapéutica muy interesante en el campo de la química médica y el descubrimiento de fármacos. Es por ello, que el objetivo principal de esta tesis doctoral ha sido la búsqueda de moduladores de mitofagia y su caracterización, así como su aplicabilidad terapéutica en modelos de neurodegeneración. Para ello, se partió de dos quimiotecas con más de 3700 compuestos en total. Se filtraron los compuestos mediante técnicas computacionales y diversidad química. Finalmente se analizaron 90 compuestos en un ensayo fenotípico de mitofagia, encontrándose dos inductores y un inhibidor. Los inductores, JAR1.39 y VP07, pertenecen a una familia de compuestos diseñados para inhibir alostericamente la quinasa GSK3. Sin embargo, la modulación de la mitofagia por parte de estos compuestos es independiente de la inhibición de GSK3, siendo su estructura la responsable de su actividad en mitofagia. Los compuestos fueron evaluados en modelos celulares de la enfermedad de Parkinson y recuperaban los bajos niveles de mitofagia que presentaban los modelos y que son característicos de la enfermedad., El inhibidor, IGS2.7, inhibe la proteína quinasa CK1, pero la inhibición de mitofagia es independiente de su diana. Proponemos ULK1, una proteína quinasa que participa en las fases iniciales del proceso de autofagia, como una nueva diana de IGS2.7. La aplicabilidad terapéutica del inhibidor se estudió en modelos de esclerosis lateral amiotrófica. Linfoblastos de pacientes con mutaciones en SOD1 y TDP-43, así como modelos murinos con mutaciones en los mismos genes, mostraron mayor flujo de autofagia comparado con sus controles. El tratamiento de ambos modelos celulares y el modelo animal de TDP-43 con el inhibidor IGS2.7 recuperó los niveles de autofagia a los del control. Por último, se propone a la proteína quinasa SGK1 como una diana para modular la homeostasis mitocondrial. Mediante un cribado virtual y posterior validación de los hits in vitro, se estudiaron los compuestos más potentes en el ensayo fenotípico de mitofagia, observándose una disminución de la mitofagia junto a un aumento de biogénesis mitocondrial. La inhibición de SGK1 fue ensayada en un modelo celular de la enfermedad de Alzheimer y se observó una recuperación de la muerte celular. Así, concluimos que la mitofagia y la homeostasis mitocondrial son procesos alterados en diferentes patologías y que su modulación es clave para recuperar los niveles adecuados de mitocondrias sanas. Por ello, aparecen como dos buenas estrategias terapéuticas para el descubrimiento de fármacos en enfermedades neurodegenerativas, en los que el proceso aparece alterado., H2020 MarieSkłodowska-Curie Actions (765912 - DRIVE), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The developing retina undergoes mitochondrial remodeling via PINK1/PRKN-dependent mitophagy

  • Zapata-Muñoz, Juan
  • Jiménez-Loygorri, Juan Ignacio
  • Stumpe, Michael
  • Villarejo-Zori, Beatriz
  • Alonso-Gil, Sandra
  • Teresak, Petra
  • Mathai, Benan J.
  • Ganley, Ian G.
  • Simonsen, Anne
  • Dengjel, Jörn
  • Boya, Patricia
15 p.-6 fig., Mitophagy, the selective degradation of mitochondria, is essential for retinal ganglion cell (RGC) differentiation and retinal homeostasis. However, the specific mitophagy pathways involved and their temporal dynamics during retinal development and maturation remain poorly understood. Using proteomics analysis of isolated mouse retinas across developmental stages and the mitophagy reporter mouse line, mito-QC, we characterized mitophagy throughout retinogenesis. While mitolysosomes were more prevalent in the mature retina, we observed two distinct mitophagy peaks during embryonic development. The first, independent of PTEN-induced kinase 1 (PINK1) activation, was associated with RGCs. The second, PINK1-dependent peak was triggered after an increase in retinal oxidative stress. This PINK1-dependent, oxidative stress-induced mitophagy pathway is conserved in mice and zebrafish, providing the first evidence of programmed, PINK1-dependent mitophagy during development., Research in the P.B. and J.D. labs are supported by grants 310030_215271 and 310030_212187 respectively, from the Swiss National Science Foundation (SNSF), and PID2021-126864NB I00 from MCIN, Spain. JZM holds a FPU fellowship from MCIN. J.I.J-L. is supported by a FPI fellowship from MCIN (PRE2019-088222) and a CNIO Friends postdoctoral fellowship. BVZ is supported by PTI+ Neuroaging from the CSIC, Spain and P.T. by the Marie Skłodowska-Curie ETN grant under the European Union’s Horizon 2020 Research and Innovation Programme (765912 DRIVE). A.S. and B.J.M are funded by the Research Council of Norway through its Centres of Excellence funding scheme (262652) and the Norwegian Cancer Society (project number 223278)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba Argemí, Guillem
  • Aguirre Plans, Joaquim, 1993-
  • Junet, Valentin
  • Segú-Vergés, Cristina
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/., Public funders provided support for authors salaries: JAP, NFF and BO received support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; “Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. GJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158. Funding for publication is from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

  • Artigas, Laura
  • Coma Camprodón, Mireia
  • Matos Filipe, Pedro
  • Aguirre Plans, Joaquim, 1993-
  • Farrés, Judith
  • Valls, Raquel
  • Fernández Fuentes, Narcís
  • Haba-Rodríguez, Juan de la
  • Olvera, Alex
  • Barbera, Jose
  • Morales-Barrera, Rafael
  • Oliva Miguel, Baldomero
  • Mas, José Manuel
From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications., LA, MC, PMF, JF, RV and JMM have commercial affiliation to Anaxomics Biotech SL. The funders provided support in the form of salaries for authors JAP, NFF and PMF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. JAP, NFF and BO acknowledge support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370].PMF has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

  • Coto-Segura, Pablo
  • Segú-Vergés, Cristina
  • Martorell, Antonio
  • Moreno-Ramírez, David
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Guerri, Filippo
  • Daura, Xavier
  • Oliva Miguel, Baldomero
  • Cara, Carlos
  • Suárez-Magdalena, Olaya
  • Abraham, Sonya
  • Mas, José Manuel
Background: Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based on patient profiles. Methods: We built a quantitative systems pharmacology (QSP) model of a clinical trial-like vPop with moderate-to-severe psoriasis treated with two dosing schemes of CZP (200 mg and 400 mg, both every two weeks for 16 weeks, starting with a loading dose of CZP 400 mg at weeks 0, 2, and 4). We applied different modelling approaches: (i) an algorithm to generate vPop according to reference population values and comorbidity frequencies in real-world populations; (ii) physiologically based pharmacokinetic (PBPK) models of CZP dosing schemes in each virtual patient; and (iii) systems biology-based models of the mechanism of action (MoA) of the drug. Results: The combination of our different modelling approaches yielded a vPop distribution and a PBPK model that aligned with existing literature. Our systems biology and QSP models reproduced known biological and clinical activity, presenting outcomes correlating with clinical efficacy measures. We identified distinct clusters of virtual patients based on their psoriasis-related protein predicted activity when treated with CZP, which could help unravel differences in drug efficacy in diverse subpopulations. Moreover, our models revealed clusters of MoA solutions irrespective of the dosing regimen employed. Conclusion: Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses., The study was funded by UCB Pharma and Anaxomics Biotech. Copy-editing was funded by UCB Pharma. Article processing fees were provided by UCB Pharma. Public funders provided support for some of the authors’ salaries: VJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158 (COSMIC; www.cosmic-h2020.eu); GJ has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912; FG has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 813545. The funder UCB Biopharma was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

  • Carcereny, Enric
  • Fernández Nistal, Alonso
  • López, Araceli
  • Montoto, Carmen
  • Naves, Andrea
  • Segú-Vergés, Cristina
  • Coma Camprodón, Mireia
  • Jorba Argemí, Guillem
  • Oliva Miguel, Baldomero
  • Mas, José Manuel
Around 3-7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyrosine kinase inhibitors (TKIs), such as crizotinib, ceritinib, alectinib, brigatinib and lorlatinb present good performance treating ALK+ NSCLC, although all patients invariably develop resistance due to ALK secondary mutations or bypass mechanisms. In the present study, we compare the potential differences between brigatinib and alectinib's mechanisms of action as first-line treatment for ALK+ NSCLC in a systems biology-based in silico setting. Therapeutic performance mapping system (TPMS) technology was used to characterize the mechanisms of action of brigatinib and alectinib and the impact of potential resistances and drug interferences with concomitant treatments. The analyses indicate that brigatinib and alectinib affect cell growth, apoptosis and immune evasion through ALK inhibition. However, brigatinib seems to achieve a more diverse downstream effect due to a broader cancer-related kinase target spectrum. Brigatinib also shows a robust effect over invasiveness and central nervous system metastasis-related mechanisms, whereas alectinib seems to have a greater impact on the immune evasion mechanism. Based on this in silico head to head study, we conclude that brigatinib shows a predicted efficacy similar to alectinib and could be a good candidate in a first-line setting against ALK+ NSCLC. Future investigation involving clinical studies will be needed to confirm these findings. These in silico systems biology-based models could be applied for exploring other unanswered questions.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Methods to develop an in silico clinical trial: computational head-to-head comparison of lisdexamfetamine and methylphenidate

  • Gutiérrez-Casares, José Ramón
  • Quintero, Javier
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Martínez, Vicente
  • Pozo-Rubio, Tamara
  • Oliva Miguel, Baldomero
  • Daura, Xavier
  • Mas, José Manuel
  • Montoto, Carmen
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with great molecular detail. Herein, we have applied a mechanistic head-to-head in silico clinical trial (ISCT) between two treatments for attention-deficit/hyperactivity disorder, to wit lisdexamfetamine (LDX) and methylphenidate (MPH). The ISCT was generated through three phases comprising (i) the molecular characterization of drugs and pathologies, (ii) the generation of adult and children virtual populations (vPOPs) totaling 2,600 individuals and the creation of physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models, and (iii) data analysis with artificial intelligence methods. The characteristics of our vPOPs were in close agreement with real reference populations extracted from clinical trials, as did our PBPK models with in vivo parameters. The mechanisms of action of LDX and MPH were obtained from QSP models combining PBPK modeling of dosing schemes and systems biology-based modeling technology, i.e., therapeutic performance mapping system. The step-by-step process described here to undertake a head-to-head ISCT would allow obtaining mechanistic conclusions that could be extrapolated or used for predictions to a certain extent at the clinical level. Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine., This study was funded by Takeda. Public funders provided support for some of the authors' salaries: GJ has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765158.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba, Guillem|||0000-0001-5209-5353
  • Aguirre-Plans, Joaquim|||0000-0002-1971-1350
  • Junet, Valentin|||0000-0002-6138-0612
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández-Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Ambra1 haploinsufficiency in cd1 mice results in metabolic alterations and exacerbates age-associated retinal degeneration

  • Ramírez Pardo, I.
  • Villarejo Zori, B.
  • Jiménez Loygorri, J. I.
  • Sierra Filardi, E.
  • Alonso Gil, S.
  • Mariño García, Guillermo|||0000-0003-1960-1677
  • Villa, P. de la
  • Fitze, P. S.
  • Fuentes, J. M.
  • García Escudero, R.
  • Ferrington, D. A.
  • Gómez Sintes, R.
  • Boya, P.
This work was supported by the H2020 Excellent Science [No. 765912]; Instituto de Salud Carlos III,CiberNed [CB06/05/0041]; Spanish Ministry of Science and Innovation [RTI2018-098990-J-I00]; Spanish Ministry of Science and Innovation [PGC2018-098557-B-I00].